BioLineRx (NASDAQ:BLRX) Announces Earnings Results, Beats Estimates By $0.07 EPS

BioLineRx (NASDAQ:BLRX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports. The company had revenue of $4.80 million during the quarter, compared to analyst estimates of $0.17 million. During the same quarter last year, the company posted ($0.09) EPS.

BioLineRx Price Performance

Shares of BioLineRx stock traded up $0.01 on Friday, reaching $1.12. 163,193 shares of the stock were exchanged, compared to its average volume of 342,065. The firm’s 50 day moving average is $1.20 and its 200-day moving average is $1.46. BioLineRx has a one year low of $0.81 and a one year high of $2.53. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.86 and a current ratio of 1.53. The firm has a market cap of $81.13 million, a PE ratio of -1.24 and a beta of 1.40.

Wall Street Analysts Forecast Growth

BLRX has been the subject of a number of recent research reports. StockNews.com raised shares of BioLineRx to a “sell” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a report on Tuesday.

Institutional Trading of BioLineRx

Several institutional investors and hedge funds have recently modified their holdings of the business. LPL Financial LLC boosted its stake in BioLineRx by 6.4% in the second quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 7,500 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in BioLineRx in the first quarter valued at about $178,000. Renaissance Technologies LLC boosted its stake in BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 189,678 shares in the last quarter. Finally, Envestnet Asset Management Inc. acquired a new stake in BioLineRx in the first quarter valued at about $88,000. 1.56% of the stock is currently owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.